A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy

Jiangdian Song(China Medical University), Jie Tian(Shanghai Jiao Tong University), Bojiang Chen(Sichuan University), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Yue Cheng, Kun Wang(Chinese Academy of Sciences), Weimin Li(Sichuan University), Changhong Liang(Guangdong Academy of Medical Sciences), Di Dong(Chinese Academy of Sciences), Ping Zhou(Capital Medical University), Ning Wu(Regeneron (United States)), Yanqi Huang(Southern Medical University), Yongzhao Zhou(Sichuan University), Mengjie Fang(Chinese Academy of Sciences), Zhenyu Liu(Shanxi Agricultural University), Yuncui Gan(Sichuan University), Zaiyi Liu(Key Laboratory of Guangdong Province), Jingyun Shi(Tongji University)
Clinical Cancer Research
March 21, 2018
Cited by 198


Related Papers